|Dr. Ted W. Love||Pres, CEO & Director||711.88k||N/A||1959|
|Dr. Charles J. Homcy||Founder, Advisor & Director||41.29k||N/A||1948|
|Mr. Jeffrey S. Farrow||Chief Financial Officer||416.22k||N/A||1962|
|Mr. Peter Radovich||Sr. VP of Operations||N/A||N/A||1978|
|Dr. Hing Sham||Sr. VP of Research||N/A||N/A||1952|
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Global Blood Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2018 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 7.